Reply to Abildgaard et al.: lot variation and inter-device differences contribute to poor analytical performance of the DCA vantage™ HbA<subscript>1c</subscript> POCT instrument in a true clinical setting.

Reply to Abildgaard et al.: lot variation and inter-device differences contribute to poor analytical performance of the DCA vantage™ HbA1c POCT instrument in a true clinical setting Unfortunately, we believe that the authors incorrectly conclude that the DCA Vantage Analyzer "does not comply with recommendations for analytical performance" and that variations from different reagent lots and instruments are the major contributors to their observation. This time frame is uncommon, and while the authors have shown that time between samples collected on two lab devices is relatively stable from 0-2 days, this does not justify use of POCT and a lab device in this same manner. [Extracted from the article]